SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has initiated further studies to support the use of its Hemopurifier® technology in cancer care. Aethlon recently documented that the Hemopurifier®, targeted to treat drug and vaccine resistant viruses, is also effective in capturing tumor derived exosomes from the blood of cancer patients. Exosomes are particles released by solid tumors, lymphomas, and leukemia, and are known to suppress the immune response in cancer patients. In studies led by Dr. Douglas Taylor at the University of Louisville, 60% of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10-minutes) through a small scale Hemopurifier®. The capture data was consistent over the course of five different studies.
